GLRX2

Across TCGA pan-cancer cohorts, GLRX2 RNA differs between tumor and matched normal tissue in 16 of 18 cancer types tested, making tumor–normal expression one of GLRX2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where GLRX2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types GLRX2 is over-expressed in tumor, although a few such as KICH and THCA show the opposite, repressed pattern.

HNSC, LIHC, and LUAD are the cancer types where GLRX2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GLRX2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	IV	+0.610	<.001	12	view →
LIHC	Male	II,III,IV	+1.554	<.001	9	view →
LUAD	Male	II,III,IV	+0.773	<.001	9	view →
KIRP	All	II,III,IV	+0.685	<.001	9	view →
STAD	All	II,III,IV	+0.562	<.001	9	view →
KIRC	Male	IV	+0.600	<.001	8	view →
BLCA	Female	All	+0.629	<.001	7	view →
BRCA	All	III,IV	+0.806	<.001	6	view →
UCEC	All	All	+0.650	<.001	6	view →
LUSC	Male	All	+0.509	<.001	6	view →
KICH	Female	All	−0.832	<.001	5	view →
COAD	All	II,III,IV	+0.407	<.001	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 16 lineages.

GLRX2–HNSC

Open the HNSC breakdown →